IMVT-1402 Shows 72.7% ACR20 Response in D2T RA; $902M Cash Runway
IMVT-1402 achieved ACR20, ACR50 and ACR70 response rates of 72.7%, 54.5% and 35.8% at Week 16 in 165 evaluable difficult-to-treat rheumatoid arthritis patients. Immunovant held $902.1 million in cash as of March 31, 2026, supporting development through a potential Graves’ disease launch and H2 2026 trial updates.
1. IMVT-1402 D2T RA Trial Results
The open-label Period 1 of the IMVT-1402 trial enrolled 170 participants with difficult-to-treat rheumatoid arthritis, 165 of whom were evaluable. At Week 16, response rates per American College of Rheumatology criteria were 72.7% (ACR20), 54.5% (ACR50) and 35.8% (ACR70), with no new safety signals observed during weekly 600 mg subcutaneous dosing.
2. Pipeline Milestones and Timelines
The proof-of-concept trial in cutaneous lupus erythematosus has fully enrolled, with topline data expected in H2 2026. Registrational studies for Graves’ disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy and Sjögren’s disease remain on track, with potential data readouts across 2026 and 2027.
3. Financial Position and Expenses
As of March 31, 2026, Immunovant reported $902.1 million in cash and equivalents, R&D expenses of $142.3 million (non-GAAP $136.0 million) and G&A expenses of $17.3 million (non-GAAP $12.4 million). Net loss for the quarter was $147.9 million, or $0.73 per share.
4. Strategic Focus Shift
Following two Phase 3 thyroid eye disease studies that did not meet primary endpoints, the batoclimab program was discontinued. Resources and clinical learnings have been redirected to accelerate IMVT-1402 development toward potential registrational trials and eventual commercial launch.